HC Wainwright Lowers Oculis (NASDAQ:OCS) Price Target to $26.00

Oculis (NASDAQ:OCS) had its target price cut by equities research analysts at HC Wainwright from $47.00 to $26.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 14.53% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC lowered their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday. Stifel Nicolaus lifted their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. Guggenheim began coverage on shares of Oculis in a research note on Wednesday, May 20th. They set a “buy” rating and a $75.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their target price on shares of Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a research note on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.75.

Oculis Price Performance

Shares of NASDAQ:OCS opened at $22.70 on Monday. The firm has a market cap of $1.32 billion, a PE ratio of -10.66 and a beta of 0.23. The firm’s fifty day moving average is $27.68 and its 200-day moving average is $25.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. Oculis has a 52 week low of $16.00 and a 52 week high of $34.47.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Sell-side analysts predict that Oculis will post -2.21 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Gildi lifeyrissjodur bought a new stake in Oculis in the fourth quarter valued at $50,250,000. Aberdeen Group plc increased its stake in Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after purchasing an additional 493,827 shares in the last quarter. SR One Capital Management LP increased its stake in Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after purchasing an additional 318,522 shares in the last quarter. Perceptive Advisors LLC bought a new stake in Oculis in the fourth quarter valued at $9,862,000. Finally, Alyeska Investment Group L.P. increased its stake in Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares in the last quarter. 22.30% of the stock is owned by institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.